Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fazarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azacitidine SCHEMBL169369 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL17537438 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL706302 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL20143987 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL10024703 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL13390797 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL23815524 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL19996985 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL1249475 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL7146234 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12857 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20250268993-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | THERIVA BIOLOGICS, INC. | 2025-08-28 | — | — | US | claimed |
| US-12318434-B2 | Alkaline phosphate-based oncology treatments | THERIVA BIOLOGICS, INC. (US) | 2025-06-03 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | claimed |
| WO-2024162488-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN | 주식회사 재인알앤피 | 2024-08-08 | — | — | WO | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0335545-B2 | Pharmaceutical formulations for parenteral use | UNIV FLORIDA (US) | 1998-09-23 | — | — | EP | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0359347-B1 | COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING | NEORX CORPORATION (US) | 1992-12-23 | — | — | EP | claimed |
| US-5024998-A | Administering in aqueous solution with cyclodextrin derivative | UNIVERSITY OF FLORIDA (US) | 1991-06-18 | — | — | US | claimed |
| US-4983586-A | Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin | UNIVERSITY OF FLORIDA (US) | 1991-01-08 | — | — | US | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0359347-A2 | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging | NEORX CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
| EP-0335545-A2 | Pharmaceutical formulations for parenteral use | UNIVERSITY OF FLORIDA (US) | 1989-10-04 | — | — | EP | claimed |